Details for Patent: 7,094,535

Title:	Nucleic acid ligands to integrins
Abstract:	Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.
Inventor(s):	Ruckman; Judy (Boulder, CO), Gold; Larry (Boulder, CO), Stephens; Andrew (Boulder, CO), Janjic; Nebojsa (Boulder, CO)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Filing Date:	Dec 18, 2001
Application Number:	10/024,997
Claims:	1. A method for detecting a site of deep vein thrombosis in an individual, the method comprising: (a) providing a nucleic acid ligand to a .alpha..sub.v.beta..sub.3 or .alpha..sub.IIb.beta..sub.3 mtegrm dimer, wherein said ligand binds to a nucleic acid binding site in said integrin .beta..sub.3 and said nucleic acid ligand conjugated to a radioactive label and wherein said nucleic acid ligand is selected from Table 1, 2 or 3; (b) administering said nucleic acid ligand to said individual; (c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique. 2. A clot-detection composition comprising a nucleic acid ligand to a .alpha..sub.v.beta..sub.3 or .alpha..sub.IIb.beta..sub.3 integrin and a pharmaceutically-acceptable excipient, wherein said ligand binds to a nucleic acid binding site in said integrin .beta..sub.3 and wherein said nucleic acid ligand is selected from Table 1, 2 or 3.